Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Leerink Partners

Stock analysts at Leerink Partners initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Wednesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $15.00 price target on the stock. Leerink Partners’ target price indicates a potential upside of 87.27% from the stock’s current price.

VYGR has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 20th. Wedbush reduced their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and a consensus target price of $17.43.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $8.01 on Wednesday. The stock’s 50 day moving average price is $6.50 and its 200 day moving average price is $7.73. Voyager Therapeutics has a 1-year low of $5.71 and a 1-year high of $11.72. The company has a market cap of $435.70 million, a PE ratio of -160.20 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period in the previous year, the firm earned ($0.51) EPS. On average, equities research analysts anticipate that Voyager Therapeutics will post -1.44 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics in the first quarter valued at about $38,000. SG Americas Securities LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at about $85,000. ProShare Advisors LLC acquired a new position in Voyager Therapeutics during the 1st quarter worth approximately $101,000. Finally, Virtus Investment Advisers Inc. purchased a new position in Voyager Therapeutics in the 1st quarter worth approximately $118,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.